These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12962793)

  • 1. Comparison of C0 and C2 cyclosporine monitoring in long-term renal transplant recipients.
    Marcén R; Pascual J; Tato A; Villafruela JJ; Teruel JL; Rivera ME; Tenorio M; Fernández M; Burgos FJ; Ortuño J
    Transplant Proc; 2003 Aug; 35(5):1780-2. PubMed ID: 12962793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients.
    Solari SG; Goldberg LR; DeNofrio D; Shaw LM
    Ther Drug Monit; 2005 Aug; 27(4):417-21. PubMed ID: 16044096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: a cost-effective strategy for reducing acute rejection.
    Balshaw R; Machnicki G; Carreño CA; Toselli L; Otero A; Keown PA
    Transplant Proc; 2005 Mar; 37(2):871-4. PubMed ID: 15848560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of cyclosporine therapeutic monitoring with C2 concentrations in stable renal allograft recipients.
    Díaz JM; Sainz Z; Guirado LL; Montañés R; Picazo M; García-Camín R; Alcaraz A; Solà R
    Transplant Proc; 2003 Aug; 35(5):1783-4. PubMed ID: 12962794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function.
    Kalyoncu M; Topaloglu R; Bayrakci U; Bakkaloglu A; Besbas N; Ozaltin F; Bakkaloglu M
    Pediatr Transplant; 2006 Mar; 10(2):168-71. PubMed ID: 16573602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
    Zhang Y; Zhang XD; Wang Y
    Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-center experience.
    Bîrsan T; Loinig C; Bodingbauer M; Wekerle T; Rockenschaub S; Berlakovich G; Soliman T; Mühlbacher F; Steininger R
    Transplantation; 2004 Dec; 78(12):1787-91. PubMed ID: 15614152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with cyclosporine: approaching the therapeutic window for C2 levels in maintenance kidney transplant recipients.
    Di Paolo S; Teutonico A; Infante B; Stallone G; Schena A; Grandaliano G; Battaglia M; Di Tonno P; Schena FP
    Transplant Proc; 2004 Mar; 36(2 Suppl):434S-436S. PubMed ID: 15041381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.
    Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J
    Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA; Veinot JP; Williams K; Haddad H; Baker A; Donaldson J; Pugliese C; Struthers C; Masters RG; Hendry PJ; Mesana T
    Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U; Ullrich S; Roskos M; Misselwitz J
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine minimization and cost reduction in renal transplant recipients receiving a C2-monitored, cyclosporine-based quadruple immunosuppressive regimen.
    Hardinger KL; Schnitzler MA; Koch MJ; Enkvetchakul D; Desai N; Jendrisak M; Lowell JA; Miller B; Shenoy S; Brennan DC
    Transplantation; 2004 Oct; 78(8):1198-203. PubMed ID: 15502720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
    Domínguez J; Fuenzalida D; Norambuena R; Pais E; Cortes Monroy G; Llanos R
    Transplant Proc; 2005 Apr; 37(3):1583-5. PubMed ID: 15866680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes and C2 cyclosporin monitoring in maintenance renal transplant recipients: 1 year follow-up study.
    Marcén R; Villafruela JJ; Pascual J; Teruel JL; Ocaña J; Tenorio MT; Burgos FJ; Ortuño J
    Nephrol Dial Transplant; 2005 Apr; 20(4):803-10. PubMed ID: 15687111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey to determine the blood concentration of cyclosporine 2 hours postdose in stable renal transplant patients.
    Jorga A; Holt DW; Yaqoob M; Whittaker C; Johnston A
    Transplant Proc; 2004 Dec; 36(10):3239-41. PubMed ID: 15686737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.